Mechanism of Microglial Recruitment in Alzheimer's Disease
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2002 - March 31, 2004
Grant ID
A2002217
Summary
The senile plaque, composed of aggregations of beta amyloid protein, is a pathological hallmark of Alzheimer’s disease. Accumulation of beta amyloid in the brain leads to the activation of microglia cells. Microglia cells are inflammatory cells that can produce substances that are toxic to neurons and lead to neuronal degeneration. Studies have shown that there are key steps for neuronal damage from the accumulation of microglia in senile plaques. First, the binding of microglia to beta amyloid occurs. Second, microglia are induced to produce chemoattractants that recruit additional microglia to the beta amyloid deposit. Finally, the production of neurotoxins from the recruited microglia cause cellular damage. Dr. El Khoury is studying the mechanisms of the recruitment of microglia to senile plaques in AD using an in vitro cellular model for microglia interactions, post-mortem human brain tissue from AD patients and transgenic mice. He plans to identify chemoattractants produced by microglia and the receptors that are involved, the expression of the chemoattractants and their receptors in brain tissue and in mouse models of AD, and the effects of disrupting the expression of chemoattractants and the receptors in the recruitment of microglia. Understanding the mechanisms of recruitment of microglia to plaques and how they become activated to produce neurotoxins may help to identify new targets for the development of treatments for AD.
Related Grants
Alzheimer's Disease Research
Defining Immunometabolic Contributions to Cognitive Impairment in Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Caleb Bailey, PhD
Current Organization
University of Kentucky Research Foundation
Defining Immunometabolic Contributions to Cognitive Impairment in Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Caleb Bailey, PhD
Current Organization
University of Kentucky Research Foundation
Alzheimer's Disease Research
Understanding the Link Between Alzheimer's Disease Risk Genes and Immune Responses in the Brain
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Amanda McQuade, PhD
Current Organization
University of California, San Francisco
Understanding the Link Between Alzheimer's Disease Risk Genes and Immune Responses in the Brain
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Amanda McQuade, PhD
Current Organization
University of California, San Francisco
Alzheimer's Disease Research
Developing a Noninvasive Gene Therapy for Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Dominika Pilat, PhD
Current Organization
Massachusetts General Hospital
Developing a Noninvasive Gene Therapy for Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Dominika Pilat, PhD
Current Organization
Massachusetts General Hospital